COMP <GO>
VCRE vs NRIX // FREE CASH FLOW YIELD
Vicore Pharma Holding AB (NASDAQ) VS. Nurix Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: VCRE 0
— NRIX 2
■ METRIC PARITY
LAST: $10.20 (+4.56%) • MKT CAP: $2.87B
fcf-yield
—
LAST: $27.12 (-0.51%) • MKT CAP: $2.96B
fcf-yield
-8.89%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VCRE VS. NRIX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VCRE | NRIX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | — | -8.89% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 54.00% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 9.52 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 3/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.9 | 63.8 | -11.90 | NRIX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.87B | $2.96B | -$91.3M | NRIX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VCRE REV | NRIX REV | VCRE GROSS % | NRIX GROSS % | VCRE FCF | NRIX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $84.0M | — | — | — | -$263.5M |
| FY 2024 | — | $54.5M | — | — | — | -$181.9M |
| FY 2023 | — | $77.0M | — | — | — | -$81.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VCRE // BETA —
NRIX // BETA —